Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Background We aimed to evaluate overall survival in US patients with amyotrophic lateral
sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Abstract Background and Objective The efficacy and safety of edaravone for the treatment of
amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to …

The etiology of amyotrophic lateral sclerosis (ALS) is unknown. Oxidative stress may be one
of the major mechanisms involved. In vitro and in vivo data of edaravone suggest that it may …

Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive and incurable
neurodegenerative disease. While pharmacotherapy options remain limited, the Food and …

Objectives The aim of the study is to analyze the ALS disease progression and respiratory
function of Italian patients treated with edaravone (EVN), as well as the adherence to, and …

Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week …